This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Cancer Immunotherapy: Combinations
Organizer(s): Chris Boshoff, Lieping Chen and Lisa Coussens
Date: March 23 - 27, 2018
Location: Fairmont The Queen Elizabeth, Montreal, QC, Canada
Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by BioLegend, Inc., Bristol-Myers Squibb Company, Cancer Research UK, Cell Research, Genentech, Inc., Incyte Corporation, MedImmune, Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology,Takeda Pharmaceutical Company Limited, TESARO, Inc. and Thermo Fisher Scientific Inc.
Summary of Meeting:
By 2025, most patients with cancer will receive immunotherapy as part of their treatment regimen. This symposium will cover the most critical topics integral to this vision: How can we integrate, sequence or combine immunotherapy with standard-of-care cytotoxic therapy, radiotherapy and targeted therapies? Which preclinical models are best predictive of combination approaches? How do we combine immune agonists as well as molecules inhibiting immune-suppressive pathways with checkpoint inhibitors? What are the rational combinations for cancer vaccines and viro-therapy? Which combinatorial approaches could prevent or treat adaptive mechanisms of resistance? Most immunotherapies are being developed in isolation, or being tested as single agents in preclinical models or in clinical studies. This conference helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical. Overall, the objectives of this meeting are to: 1) Elucidate rational combinations for immunotherapy; 2) Discuss preclinical and other models to inform combinatorial approaches; 3) Understand the relevance for biomarker approaches; and 4) Provide insights into the latest preclinical and clinical data for immunotherapy combinations.
Scholarship Deadline: November 21 2017
Discounted Abstract Deadline: November 21 2017
Abstract Deadline: December 19 2017
Discounted Registration Deadline: January 16 2018
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
BioLegend, Inc.Bristol-Myers Squibb CompanyCancer Research UKCell ResearchGenentech, Inc.Incyte CorporationMedImmuneMerck & Co., Inc.OncoMed Pharmaceuticals, Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.Surface OncologyTakeda Pharmaceutical Company LimitedTESARO, Inc.Thermo Fisher Scientific Inc.
We gratefully acknowledge additional support from these exhibitors at this conference:
Caprion Biosciences Inc.Immudex USA, LLC
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)American Society of Gene & Cell Therapy (ASGCT)Avanti Polar Lipids, Inc.Bethyl Laboratories, Inc.Charles RiverEurofins Pharma Discovery ServicesInfinity Pharmaceuticals, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.

Pfizer Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA224868-01
Funding for this conference was made possible (in part) by 1 R13 CA224868-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found